Physician profile
Mikhail E Altan
NPI 1265248561
$2,495.43
in general payments reported to CMS, 2019-2025
14 companies · $2,495 in 2025
The $2,495 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.43 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $462.03 | 2025 | Rezdiffra |
| Abbvie INC. | $457.34 | 2025 | |
| Janssen Biotech, INC. | $293.84 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $256.52 | 2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $231.50 | 2025 | Omvoh |
| Gilead Sciences, INC. | $179.55 | 2025 | |
| Pfizer INC. | $153.39 | 2025 | |
| Qol Medical, LLC | $110.80 | 2025 | Sucraid |
| Ardelyx, INC. | $91.17 | 2025 | Ibsrela |
| Novo Nordisk INC | $90.00 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.29 | 2025 | Relistor |
| Celltrion USA INC. | $47.44 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $42.54 | 2025 | |
| Braintree Laboratories, INC. | $15.02 | 2025 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Altan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.